PreveCeutical Medical Chairman Stephen Van Deventer joined Steve Darling from Proactive to share updates on the company’s strategic advances in gene therapy and its wholly-owned subsidiary, BioGene Therapeutics. BioGene focuses on addressing diabetes and obesity through innovative therapies targeting the PTP1B gene in the brain, which is also linked to colon and breast cancers. Van Deventer emphasized the global need for new treatments in diabetes and obesity as key reasons for selecting these areas as initial targets.
He stated, “Once we manage to get the proof of concept done and get it to commercialization, it's a very viable business plan.” The advancements aim to provide solutions for widespread health challenges while establishing a robust business opportunity. The conversation also underscored the strength of BioGene’s team, which boasts deep scientific and corporate expertise, positioning the subsidiary to drive success in its mission. Looking ahead, PreveCeutical plans to further its other programs by 2025.
These include its Sol-Gel drug delivery platform, designed for efficient medication delivery, and its non-addictive analgesic program, which addresses pain management without the risk of addiction. #proactiveinvestors #preveceutical #biogenetherapeutics #cse #prev #otcqb #prvcf BioGeneTherapeutics #GeneTherapy #DiabetesTreatment #ObesitySolutions #BiotechInnovation #PTP1B #MedicalResearch #HealthcareInnovation#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews